Statement of Changes in Beneficial Ownership (4)
December 17 2021 - 4:01PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Martin Daniel C. |
2. Issuer Name and Ticker or Trading Symbol
Deciphera Pharmaceuticals, Inc.
[
DCPH
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Commercial Officer |
(Last)
(First)
(Middle)
C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET |
3. Date of Earliest Transaction
(MM/DD/YYYY)
12/15/2021 |
(Street)
WALTHAM, MA 02451
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 12/15/2021 | | A(1) | | 8300 | A | $0.00 | 36147 (2)(3) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Buy) | $9.23 | 12/15/2021 | | A | | 62971 | | (4) | 12/14/2031 | Common Stock | 62971 | $0.00 | 62971 | D | |
Explanation of Responses: |
(1) | The reporting person was awarded 8,300 Restricted Stock Units ("RSUs") under the Issuer's 2017 Stock Option and Incentive Plan (the "2017 Plan"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in two equal installments on June 15, 2022 and June 15, 2023, subject to continuous service with the Issuer or a Subsidiary (as defined in the 2017 Plan) through such dates. The RSUs may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
(2) | This number includes (i) 5,280 RSUs issued pursuant to the 2017 Plan which vest in three (3) equal annual installments on each of February 15, 2022, 2023 and 2024; and (ii) 8,300 RSUs issued pursuant to the 2017 Plan which vest in equal annual installments over four (4) years beginning on February 15, 2022. Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock. The RSUs may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
(3) | Includes 145 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 12, 2021. |
(4) | This stock option was issued pursuant to the 2017 Plan. The option shall vest in two equal installments on June 15, 2022 and June 15, 2023, subject to continuous service with the Issuer or a Subsidiary (as defined in the 2017 Plan) through each vesting date. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Martin Daniel C. C/O DECIPHERA PHARMACEUTICALS, INC. 200 SMITH STREET WALTHAM, MA 02451 |
|
| Chief Commercial Officer |
|
Signatures
|
/s/ Jeffrey Held, Attorney-in-Fact | | 12/17/2021 |
**Signature of Reporting Person | Date |
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From May 2024 to Jun 2024
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Jun 2023 to Jun 2024